Sensus Healthcare’s shares plunged 24.7% after earnings, driven by cautious outlook signals and execution risks around the transition to the new CPT code environment, despite management’s positive framing of increasing adoption and pipeline development.

• The company highlighted a pivotal transition to new CPT codes for superficial radiotherapy and is focused on educating the market and driving adoption.
• Reported shipments included 14 SRT systems with progress in diversifying the customer base and reducing historical customer concentration, matching Q4 levels.
• Treatment volumes increased 8% year-over-year, supported by 18 active FDA sites and 9 pending activations, fueling recurring revenue streams estimated at ~10% of total revenue.
• Launched new financial services and SensusLink software to drive recurring revenue, aiming to shift customer preferences from rental agreements to purchases.
• Despite these initiatives, investors reacted negatively, likely signaling disappointment in either the pace of execution, deceleration risks, or concerns over profitability and sustainable margin improvement amid ongoing market uncertainty.